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ABSTRACT
Introduction. Plaque-type psoriasis affecting the nails, scalp, hands or feet can often be difﬁcult to treat; for
example, topical treatments and phototherapy may not penetrate the nail plate or scalp. The objective of this
large, international, multicentre study was to investigate the efﬁcacy of efalizumab in a Latin American population
of adult patients with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or
phototherapy.
Methods. Eligible patients were enrolled in a 24-week, open-label, single-arm, Phase IIIb/IV study of continuous
treatment with subcutaneous efalizumab, 1.0 mg/kg/wk. Involvement of the nails, scalp, or hands or feet was assessed
using the Nail Psoriasis Severity Index (NAPSI), the Psoriasis Scalp Severity Index (PSSI), or the Palmoplantar
Pustulosis Psoriasis Area and Severity Index (PPPASI), respectively. Missing data were handled using a last obser-
vation carried forward or nonresponder imputation approach.
Results. Of the 189 patients who received treatment, 112 patients had nail involvement, 172 had scalp involvement,
and 19 had palmoplantar disease at baseline. At Week 24, 50% improvement on the NAPSI, PSSI and PPPASI was
observed in 31%, 71% and 68% of patients, respectively, whereas 75% improvement on these scores was observed
in 17%, 52% and 63%, respectively. Descriptive statistics showed lower NAPSI-75 and higher PSSI-75 and -50
response rates among patients with higher baseline scores.
Conclusions. This open-label, uncontrolled study provides supportive evidence of the potential of efalizumab as a
treatment for nail, scalp and palmoplantar psoriasis.
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Introduction
P
soriasis is a chronic, autoimmune, T-cell-
mediated inﬂammatory skin disorder that
affects various parts of the body [1]. Psoriasis
occurs in approximately 1–3% of the population in
Europe and the USA [2–4]. The nails, scalp, palms
and soles of the feet are especially problematic
sites in the everyday treatment of psoriasis [5]. In
particular, the nails and scalp are not amenable to
1
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of the impermeability of the nail plate and the
protective effects of hair on the scalp [6–8].
Efalizumab is a recombinant, humanized,
monoclonal, immunoglobulin G1 antibody that
binds speciﬁcally to the CD11a subunit of leuco-
cyte function-associated antigen-1, inhibiting
major steps in the immunopathogenesis of psoria-
sis: T-cell activation, migration and reactivation
[9]. The efﬁcacy and safety of efalizumab
1.0 mg/kg/wk in the treatment of moderate-to-
severe plaque psoriasis have been demonstrated in
an extensive clinical trial programme conducted
in Europe and North America [10–15]. At the
time this study was completed, efalizumab
was approved for the treatment of adults with
moderate-to-severe, chronic plaque psoriasis.
In previous studies of efalizumab, efﬁcacy was
assessed using the Psoriasis Area and Severity
Index (PASI); no previous detailed analyses of the
efﬁcacy of this agent in the treatment of nail, scalp
and palmoplantar psoriasis have been published to
date. This multicentre, open-label, Phase IIIb/IV
trial examined the efﬁcacy of efalizumab in a popu-
lation of patients with psoriasis in Latin America;
primary efﬁcacy and safety results were presented
by Stengel et al. at the 2008 5th Spring Sympo-
sium of the European Academy of Dermatology
and Venereology and are reported elsewhere [16].
Here, we present analyses of data from subgroups
of patients with nail, scalp or palmoplantar psoria-
tic involvement at study entry.
Methods
This was a 24-week, multicentre, open-label,
single-arm, Phase IIIb/IV study (protocol
IMP25161; ClinicalTrials.gov registration
NCT00287118) conducted between October
2004 and May 2006 in 23 centres in Latin America
(ﬁve in Argentina, nine in Brazil, and nine in
Mexico). The reader is referred to Stengel et al.
(this volume) for a complete brieﬁng of the
methodology.
Patients
Patients were between 18 and 75 years of age and
had moderate-to-severe plaque psoriasis (10%
body surface area involved and candidates for sys-
temic therapy or phototherapy). Discontinuation
of any systemic psoriasis treatment was required
prior to commencement of the trial; in the case of
biologics, a 3-month washout period was required.
For women of childbearing potential and for men
whose partners could become pregnant, consent to
use an acceptable method of contraception and
agreement to continue to practise an acceptable
method of contraception for the duration of their
participation in the trial and up to 3 months after
the last dose of efalizumab, were mandatory for
study participation. The dosage of any medica-
tions required for treatment of comorbidities must
have been stable for at least 28 days before the
administration of study drug. All patients under-
went initial screening 14 days prior to the ﬁrst
efalizumab injection. Discontinuation of any sys-
temic psoriasis treatment was mandatory before
starting study medication; no washout period was
required. Patients included in the subgroup analy-
ses had baseline scores > 0 on the Nail Psoriasis
Severity Index (NAPSI) [17], indicating nail
involvement at baseline; the Psoriasis Scalp Sever-
ity Index (PSSI) [18], indicating scalp involvement;
or the Palmoplantar Pustulosis Psoriasis Area and
Severity Index (PPPASI) [19], indicating involve-
ment of the palms and/or soles. Key exclusion
criteria included guttate, erythrodermic or pustu-
lar psoriasis as the sole or predominant form of
psoriasis. Patients were also ineligible if they had
active disease rebound during or following discon-
tinuation of previous efalizumab treatment (i.e. a
PASI >125% from baseline and/or new predomi-
nant morphology of psoriasis) if this outcome was
related to efalizumab adverse events or related to
lack of efalizumab efﬁcacy; however, if active
disease rebound was related to a nondrug reason
(e.g. infection or vaccination) then patients were
eligible for study drug medication. The study was
carried out in compliance with the Declaration of
Helsinki and Good Clinical Practice guidelines,
and the protocol was approved by the research
ethics committees of the centres involved. Patients
were informed of the objectives and overall
requirements of the study, and all gave written
informed consent.
Treatment
All patients received open-label efalizumab admin-
istered subcutaneously, starting with an initial con-
ditioning dose of 0.7 mg/kg at baseline (study day
0), followed by 23 weekly doses of efalizumab
1.0 mg/kg. Injection sites were rotated on a weekly
basis and efalizumab was self-administered by
patients after the ﬁrst injection.
Efﬁcacy Assessments
The primary efﬁcacy endpoint in the parent trial
was the proportion of patients with a rating of
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dynamic Physician Global Assessment (PGA), a
tool that measures the response of all psoriatic
lesions to therapy by comparing the subject’s
present condition to baseline photographs or body
diagrams. The assessor classiﬁed response by con-
sidering erythema, scaling, plaque thickness and
percentage of body surface area affected. Ratings
of cleared and excellent represented a 100%
improvement (remission) and 75% to 99%
improvement of all clinical signs and symptoms
relative to baseline, respectively. The nail, scalp
and palmoplantar endpoints, which were tertiary
endpoints in the parent trial, are presented in
detail here. The median percentage improvements
over time in NAPSI, PSSI and PPPASI scores are
reported for the subgroups of patients who had
baseline scores > 0 for these indices, as well as the
percentages of patients showing at least a 50% and
75% improvement in these scores between base-
line and Week 24.
Assessment of nail psoriasis was made using the
NAPSI (score range 0–80, with higher scores indi-
cating greater involvement; all involved nails are
assessed), at baseline and at Weeks 12 and 24.
Assessment of scalp psoriasis was made using the
PSSI (score range 0–72, with higher scores indi-
cating more severe disease). Palmoplantar psoria-
sis was assessed using the PPPASI (score range
0–72, with higher scores indicating more severe
disease). Both the PSSI and PPPASI were mea-
sured at baseline and at Weeks 4, 8, 12 and 24 (or
at the time of last dose).
Statistical Analysis
Analyses of efﬁcacy in the intent-to-treat (ITT)
population were performed using the last observa-
tion carried forward (LOCF) approach. The
primary endpoint was also analysed using the non-
responder imputation, in which all patients with
missing data at Week 24 were counted as non-
responders. No formal hypothesis testing or
adjusted analyses were performed. Analysis was
performed using SAS software (SAS Institute, Inc.,
Cary, NC, USA).
The efﬁcacy data reported here for nail, scalp
and palmoplantar psoriasis are for the subsets of
patients who had scores on the NAPSI, PSSI and
PPPASI that were >0 at baseline (i.e. patients who
had some nail, scalp or palmoplantar disease at
baseline). Demographic and treatment data are for
the entire ITT population. Summary statistics
were determined for scores; 95% conﬁdence inter-
vals (CIs) for the median were estimated using the
exact method based on the binomial distribution.
For proportions, exact CIs were used. The analysis
of patients showing 50% and 75% improvement in
NAPSI, PSSI and PPPASI scores was post hoc.
Results
Demographic and Disease Characteristics
Overall, 189 patients were enrolled and received
treatment (ITT population), of whom 137
(72.5%) completed the 24-week treatment period
(Table 1). A total of 30 and 11 patients discontin-
ued treatment due to adverse events and lack of
efﬁcacy, respectively. Eleven other patients did not
complete the treatment course for a range of other
reasons, including loss to follow-up and protocol
violations. These factors, as well as failure to
record all patient data sets (and their associated
statistical descriptors), accounted for most of the
missing datapoints. The median (range) age in the
ITT population was 46 (19–74) years and two-
thirds of patients enrolled were men. Hispanics or
Latinos comprised the majority ethnic group in
this population (104/189 [55%]). A total of 112
patients had nail involvement, 172 had scalp
involvement and 19 had palmoplantar involve-
ment at baseline; 1 of these 19 patients had pus-
tules at baseline.
Table 1 Summary of baseline patient demographic and
disease characteristics
Characteristic
ITT population
(N = 189)
Age in years, median (range) 46 (19–74)
Male sex, n (%) 134 (70.9)
Race, n (%)
White 125 (66.1)
Black 7 (3.7)
Asian 0 (0.0)
Other 57 (30.2)
Hispanic or Latino ethnicity, n (%) 104 (55.0)
Weight in kg, median (range) 80 (46–120)
BMI, kg/m
2, median (range)* 28.7 (16.5–45.3)
Duration of psoriasis, median years (range)
† 15 (1–46)
Patients with prior psoriasis therapy, n (%) 158 (83.6)
Patients with prior systemic therapy, n (%) 153 (81.0)
PASI score, median (range)
† 22 (7–61)
PASI score  20, n (%)
† 111 (59.0)
NAPSI score > 0, n (%) 112 (59.3)
PSSI score > 0, n (%) 172 (91.0)
PPPASI score > 0, n (%) 19 (10.1)
*N = 180.
†N = 188.
BMI = body mass index; ITT = intent-to-treat; NAPSI = Nail and Psoriasis
Severity Index; PASI = Psoriasis Area and Severity Index; PPPASI =
Palmoplantar Pustulosis Psoriasis Area and Severity Index; PSSI = Psoriasis
Scalp Severity Index.
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The mean (SD) time on study (including follow-
up) for the entire treatment group was 202 (52.9)
days and the mean (SD) time on treatment was 139
(45.1) days. Almost two-thirds of patients (122/189
[64.6%]) received all 24 planned weekly injections;
the mean (SD) number of injections received was
20 (6.4).
In the ITT population, 48.7% (92/189; 95%
CI: 41.6–55.8%) of patients achieved or main-
tained a PGA score of “excellent” or “cleared” at
Week 24. Using the nonresponder imputation,
46.0% (87/189; 95% CI: 38.9–53.1%) achieved
this endpoint.
At baseline, 112 patients had nail psoriasis, with
a median (range) score on the NAPSI of 14 (1–80)
(Table 2). At Week 12, the median percentage
improvement in the NAPSI was 0. At Week 24,
the median percentage improvement from base-
line in the NAPSI was 14.3% (95% CI: 0–29.4%;
32 missing values imputed). At this time point,
31% of patients with nail disease at baseline had
achieved at least 50% improvement in the NAPSI
score and 17% had at least a 75% improvement
(Figure 1a).
Among patients with nail involvement at base-
line, 31% had a NAPSI score of 7, 22% had a
score of >7t o14, 14% had a score of >14 to
21, 11% had a score of >21 to 28, and 21%
had a score of >28. The proportions of patients in
these categories showing at least a 75% improve-
ment in NAPSI score at endpoint were 26%,
24%, 6%, 8% and 8%, respectively, indicating
that rates of 75% improvement on the NAPSI
were lower when the baseline score was higher.
Corresponding proportions of patients in the cat-
egories deﬁned by baseline score who showed at
least a 50% improvement in NAPSI score at
endpoint were 37%, 32%, 19%, 17% and 38%,
respectively.
A total of 172 patients had scalp disease at base-
line, with a median (range) PSSI score of 16 (1–54)
(Table 2). At Week 24, the median percentage
improvement from baseline in PSSI score was
77.6% (95% CI: 66.7–85.7%; 46 missing values
imputed). At this time point, 71% of patients with
scalp psoriasis at baseline had achieved at least
50% improvement in the PSSI score and 52%
showed at least a 75% improvement (Figure 1a).
These proportions were 58% and 43%, respec-
tively, when the 46 patients with missing data were
considered as nonresponders. An improvement in
PSSI score was evident as early as Week 4 of treat-
ment, and continued to increase throughout the
treatment period (Figure 1b).
At baseline, the proportions of patients with
PSSI scores of 7, >7t o14, >14 to 21, >21 to
28, and >28 were 30%, 13%, 17%, 12% and
27%, respectively. The proportions of patients in
these categories who showed at least a 75%
improvement in PSSI score at Week 24 were 29%,
70%, 57%, 75% and 55%, respectively. The pro-
portions of patients in the categories deﬁned by
baseline score who showed a 50% improvement in
PSSI were 52%, 83%, 83%, 85% and 72%,
respectively. These ﬁndings indicate that baseline
PSSI scores >7 were associated with higher
response rates than scores 7.
In 19 patients who had palmoplantar disease at
baseline, the median (range) baseline PPPASI
score was 2 (0–20) (Table 2). One patient had pus-
tules at baseline, a corresponding PPPASI baseline
score of 20.4, and a score of 0 at Week 24. At
Week 24, the median percentage improvement
from baseline in PPPASI was 100% (95% CI:
0–100%; 6 missing values imputed). At this time
point, 68% of patients showed at least a 50%
improvement and 63% showed at least a 75%
improvement in PPPASI (Figure 1a). An improve-
ment in PPPASI score was seen early in treatment,
at Week 4 (51.0%; 95% CI: 0–83.3%), and con-
tinued to improve throughout the treatment
period (91.7% [95% CI: 71.9–100%] at Week 8
and 97.5% [95% CI: 51.0–100.0%] at Week 12).
Table 2 Median (interquartile range) Nail and Psoriasis Severity Index (NAPSI), Psoriasis Scalp Severity Index (PSSI),
and Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) scores at baseline and at Week 24 among Latin
American patients with scalp, palmoplantar and nail psoriasis who received subcutaneous efalizumab 1.0 mg/kg/wk in an
open-label, noncomparative study
Measure (sample size)
Baseline Week 24 visit
No imputation LOCF No imputation LOCF
NAPSI (N = 112) 14.0 (6.0–27.0) 14.0 (6.0–27.0) 10.0 (2.0–17.0) 11.0 (4.0–20.0)
PSSI (N = 172) 16.0 (6.0–30.0) 16.0 (6.0–30.0) 3.0 (0.0–6.0) 3.0 (1.0–8.0)
PPPASI (N = 19) 2.0 (1.0–6.0) 2.0 (1.0–6.0) 0.0 (0.0–0.0) 0.0 (0.0–2.0)
LOCF = last observation carried forward.
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score was <2 for 11 patients, and between 2 and 8
for 5 patients; 3 patients had high scores (19.2,
19.6 and 20.4). Of those with low baseline scores
(<2), 6 achieved a score of 0 on the PPPASI, 3
experienced worsening, and 2 withdrew from the
study without an on-treatment PPPASI evalua-
tion. Of the 5 patients with a baseline PPPASI
score in the range 2–8, 4 had no psoriasis involve-
ment after 24 weeks of treatment, whereas the
remaining patient experienced worsening. The 3
patients with high baseline scores on the PPPASI
experienced improvements of 51%, 98% and
100%.
The safety and tolerability of efalizumab are
reported elsewhere [16].
No new safety concerns were identiﬁed in this
population.
Discussion
To our knowledge, this was the ﬁrst large, prospec-
tive, international, multicentre study of any bio-
logical therapy in patients with psoriasis in Latin
America. It was also the ﬁrst study to assess the
efﬁcacy of efalizumab in the treatment of nail,
scalp and palmoplantar psoriasis using the NAPSI,
PSSI, and PPPASI, although these measures were
not the primary endpoint of the parent trial.
Scalp psoriasis, which is currently difﬁcult to
treat in clinical practice, showed particularly
promising results with efalizumab treatment
during this trial, as measured by change from base-
line PSSI score. Although the PSSI results
reported were less impressive when using a non-
responder imputation than the more optimistic
LOCF approach, we believe that the difference
between these approaches was due more to the
level of control of the patient’s overall psoriasis
than missing values for PSSI scores, which
improved early and continued to improve
throughout the study period. In addition, given
that this was one of the largest clinical trials to date
reporting the effect of any treatment on nail pso-
riasis, it could be concluded that the improvement
achieved in nail psoriasis was clinically meaningful,
as approximately one-third of patients achieved at
least a 50% improvement from baseline NAPSI
score.
The results for nail and palmoplantar psoriasis
in the present study are in agreement with those
reported from a comparison of efalizumab with
placebo in patients with hand and foot plaque
psoriasis [20]. In that study, 48% of patients
achieved a PGA rating of “clear”, “almost clear” or
“mild” disease after 12 weeks of treatment with
efalizumab.
As topical therapies are generally the ﬁrst-line
treatment for nail, scalp and palmoplantar psoria-
sis, and systemic treatments are generally reserved
a
b
Figure 1 (a) Proportion of patients with at least 50% and
75% improvement in Nail Psoriasis Severity Index (NAPSI),
Psoriasis Scalp Severity Index (PSSI), and Palmoplantar
Pustulosis Psoriasis Area and Severity Index (PPPASI)
scores at Week 24. Patients with: *NAPSI > 0 at baseline,
†PSSI > 0 at baseline, and
‡PPPASI > 0 at baseline. (b)
Median (95% conﬁdence interval) percentage improvement
in Psoriasis Scalp Severity Index (PSSI) scores over
time (N = 172) among patients with a PSSI score of >0a t
baseline.
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ments have usually been assessed only in small
clinical trials. Conventional systemic therapies,
such as retinoids, ciclosporin and methotrexate,
have proved effective against psoriasis in these
locations, but their use is limited by contraindica-
tions and potential toxicities [8,21,23]. Reports of
the use of biological therapies in patients with
scalp, nail, hand or foot psoriasis have mainly been
restricted to small clinical trials or case studies.
The exception is inﬂiximab, which has been
reported to show good efﬁcacy against nail psoria-
sis in a large, randomized, placebo-controlled
study [24,25], as well as in smaller studies [26,27].
However, no such efﬁcacy has been reported for
inﬂiximab against palmoplantar or scalp psoriasis.
Indeed, de novo manifestation of palmoplantar and
scalp psoriasis has been reported during treatment
with inﬂiximab [28–30]. Clinical activity against
nail psoriasis has been reported for alefacept in
small, open-label trials and case series [31–33], and
for etanercept in a case study [34]. In a small,
open-label study, alefacept has been reported to
have some efﬁcacy against scalp psoriasis [35] and
this agent has also shown promising activity
against palmoplantar psoriasis in case studies
[36,37] and small open-label trials [38,39]. In a
small randomized clinical trial, some clinical activ-
ity against palmoplantar disease was reported with
etanercept [40] and, in a retrospective study, etan-
ercept was reported to reduce nail psoriasis during
initial and repeated treatments [41]. Larger clinical
trials are needed to conﬁrm these ﬁndings.
The encouraging results from the current study
are limited by the fact that this was an open-label
trial with no comparator group, and that it
involved patients with a wide range of disease
severity affecting the nails, scalp and palmoplantar
regions. Many of the patients also had relatively
low baseline scores on the NAPSI, PSSI and
PPPASI. For example, in other studies a NAPSI
score of 15 has been considered to represent
moderate-to-severe disease [32,42], whereas in the
present study the median baseline score was 14.
Furthermore, low baseline scores might have
limited the treatment effects seen in individual
patients and the median change seen in the group
overall (or, in the case of the PPPASI, produced an
unusually large treatment effect in patients with
low baseline scores). However, despite these limi-
tations, this study provides evidence of the poten-
tial of efalizumab as a treatment for nail, scalp and
palmoplantar psoriasis. Large controlled studies
would be needed to conﬁrm these initial results.
However, opportunistic infections have been
reported in the post-marketing surveillance in
patients with psoriasis receiving efalizumab. In
particular, cases of JC virus infection resulting in
progressive multifocal leucoencephalopathy have
been reported in patients receiving efalizumab
continuously for more than 3 years. After evaluat-
ing all available safety data, the European Medi-
cines Agency concluded that the beneﬁts of
efalizumab treatment no longer outweighed the
risks associated with the drug and recommended
suspension of marketing authorisation on 19 Feb-
ruary 2009. The drug has also been voluntarily
withdrawn from the US market.
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